Adaptive Immune Responses and HER2/neu-Positive Breast Cancer

Eric D. Mortenson, Yang-Xin Fu

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Oncogenic signaling, such as HER2/neu signaling, has been shown to play a major role in tumorigenesis in a subset of breast cancer patients. The use of anti-HER2/neu antibody has not only revealed the mechanisms for HER2/neu signaling, but has also shown a therapeutic advantage of its blockade. The use of trastuzumab has greatly improved the treatment of HER2-positive breast cancer. Although this therapy has been used in the clinic for over 20 years, recent data are still uncovering new mechanisms by which this antibody exerts its antitumor activity. In addition to improved understanding of the molecular mechanisms by which this therapy inhibits growth of tumor cells, it has been discovered that anti-HE2/neu therapy initiates and requires the adaptive immune system. The presence of anti-HER2/neu-initiated adaptive immunity gives credence to efforts targeted at stimulating the immune system in treating HER2-positive breast cancer. This review focuses on the role of the inflammatory response in HER2-positive breast cancer with particular emphasis on trastuzumab therapy.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalCurrent Pathobiology Reports
Volume1
Issue number1
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Fingerprint

Adaptive Immunity
Breast Neoplasms
Immune System
Therapeutics
Antibodies
Carcinogenesis
Growth
Neoplasms

Keywords

  • Adaptive immunity
  • Antibody therapies
  • Breast cancer
  • HER2/neu
  • Oncogenic signaling

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Pathology and Forensic Medicine
  • Cancer Research

Cite this

Adaptive Immune Responses and HER2/neu-Positive Breast Cancer. / Mortenson, Eric D.; Fu, Yang-Xin.

In: Current Pathobiology Reports, Vol. 1, No. 1, 01.03.2013, p. 37-42.

Research output: Contribution to journalReview article

@article{aab0187fbee74d048e3498d66ebc0141,
title = "Adaptive Immune Responses and HER2/neu-Positive Breast Cancer",
abstract = "Oncogenic signaling, such as HER2/neu signaling, has been shown to play a major role in tumorigenesis in a subset of breast cancer patients. The use of anti-HER2/neu antibody has not only revealed the mechanisms for HER2/neu signaling, but has also shown a therapeutic advantage of its blockade. The use of trastuzumab has greatly improved the treatment of HER2-positive breast cancer. Although this therapy has been used in the clinic for over 20 years, recent data are still uncovering new mechanisms by which this antibody exerts its antitumor activity. In addition to improved understanding of the molecular mechanisms by which this therapy inhibits growth of tumor cells, it has been discovered that anti-HE2/neu therapy initiates and requires the adaptive immune system. The presence of anti-HER2/neu-initiated adaptive immunity gives credence to efforts targeted at stimulating the immune system in treating HER2-positive breast cancer. This review focuses on the role of the inflammatory response in HER2-positive breast cancer with particular emphasis on trastuzumab therapy.",
keywords = "Adaptive immunity, Antibody therapies, Breast cancer, HER2/neu, Oncogenic signaling",
author = "Mortenson, {Eric D.} and Yang-Xin Fu",
year = "2013",
month = "3",
day = "1",
doi = "10.1007/s40139-012-0001-8",
language = "English (US)",
volume = "1",
pages = "37--42",
journal = "Current Pathobiology Reports",
issn = "2167-485X",
publisher = "Springer US",
number = "1",

}

TY - JOUR

T1 - Adaptive Immune Responses and HER2/neu-Positive Breast Cancer

AU - Mortenson, Eric D.

AU - Fu, Yang-Xin

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Oncogenic signaling, such as HER2/neu signaling, has been shown to play a major role in tumorigenesis in a subset of breast cancer patients. The use of anti-HER2/neu antibody has not only revealed the mechanisms for HER2/neu signaling, but has also shown a therapeutic advantage of its blockade. The use of trastuzumab has greatly improved the treatment of HER2-positive breast cancer. Although this therapy has been used in the clinic for over 20 years, recent data are still uncovering new mechanisms by which this antibody exerts its antitumor activity. In addition to improved understanding of the molecular mechanisms by which this therapy inhibits growth of tumor cells, it has been discovered that anti-HE2/neu therapy initiates and requires the adaptive immune system. The presence of anti-HER2/neu-initiated adaptive immunity gives credence to efforts targeted at stimulating the immune system in treating HER2-positive breast cancer. This review focuses on the role of the inflammatory response in HER2-positive breast cancer with particular emphasis on trastuzumab therapy.

AB - Oncogenic signaling, such as HER2/neu signaling, has been shown to play a major role in tumorigenesis in a subset of breast cancer patients. The use of anti-HER2/neu antibody has not only revealed the mechanisms for HER2/neu signaling, but has also shown a therapeutic advantage of its blockade. The use of trastuzumab has greatly improved the treatment of HER2-positive breast cancer. Although this therapy has been used in the clinic for over 20 years, recent data are still uncovering new mechanisms by which this antibody exerts its antitumor activity. In addition to improved understanding of the molecular mechanisms by which this therapy inhibits growth of tumor cells, it has been discovered that anti-HE2/neu therapy initiates and requires the adaptive immune system. The presence of anti-HER2/neu-initiated adaptive immunity gives credence to efforts targeted at stimulating the immune system in treating HER2-positive breast cancer. This review focuses on the role of the inflammatory response in HER2-positive breast cancer with particular emphasis on trastuzumab therapy.

KW - Adaptive immunity

KW - Antibody therapies

KW - Breast cancer

KW - HER2/neu

KW - Oncogenic signaling

UR - http://www.scopus.com/inward/record.url?scp=84925295050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925295050&partnerID=8YFLogxK

U2 - 10.1007/s40139-012-0001-8

DO - 10.1007/s40139-012-0001-8

M3 - Review article

C2 - 23420038

AN - SCOPUS:84925295050

VL - 1

SP - 37

EP - 42

JO - Current Pathobiology Reports

JF - Current Pathobiology Reports

SN - 2167-485X

IS - 1

ER -